REFERANCE

1. M. Hosseini, A. Tizmaghz, H. Alizadeh Otaghvar, M. ShamsThe Prevalence of Fibrocystic changes of breast tissue of patients who underwent reduction mammoplasty in Rasool-Akram, Firuzgar and Sadr Hospitals during 2007–2012Adv Surg Sci, 2 (1) (2014), pp. 5-8(12)

2. Jemal A, Bray F, Center MM, Ferlay J, *et al.* Global cancer statistics. CA: A Cancer Journal for Clinicians 2011;61:69-90.

3. M. Bendre, D. Gaddy, R.W. Nicholas, L.J. SuvaBreast cancer metastasis to bone: it is not all about PTHrPClin Orthop Relat Res, 415 (2003), pp. S39-S45

4. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, *et al.*Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med, 344 (11) (2001), pp. 783-792

5. L.J. Suva, R.J. Griffin, I. MakhoulMechanisms of bone metastases of breast cancerEndocr Relat Cancer, 16 (3) (2009), pp. 703-713

6. M.E. Shaffrey, M. Mut, A.L. Asher, S.H. Burri, A. Chahlavi, S.M. Chang, *et al.*Brain metastasesCurr Probl Surg, 41 (8) (2004), pp. 665-741

7. R.E. ColemanAdjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?Eur J Cancer, 45 (11) (2009), pp. 1909-1915

8. R.L. Theriault, G.N. HortobagyiBone metastasis in breast cancerAnticancer Drugs, 3 (5) (1992), pp. 455-462

9. LiptonBone metastases in breast cancerCurr Treat Options Oncol, 4 (2) (2003), pp. 151-158

10. D. Palmieri, Q.R. Smith, P.R. Lockman, J. Bronder, B. Gril, A.F. Chambers, *et al.*Brain metastases of breast cancerBreast Dis, 26 (2006–2007), pp. 139-147

11. Yin W, Chen B, Tian F, Yu Y and Kong FM. The Growth of Radiation Oncology in Mainland China during the last 10 Years. Int J Radiat Oncol Biol Phys 2008, 70(3):795-798.

12. Cardoso F, Harbeck N, Fallowfield L, *et al*. Locally recurrent or metastatic breast cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2012;23:vii11-vii9.

13. INTERNATIONAL ATOMIC ENERGY AGENCY. Setting up a RadiotherapyProgram: Clinical, Medical Physics, Radiation Protection and Safety Aspects,International Atomic Energy Agency, Vienna, Austria 2008.

14. Cleeland, C.S. and K.M. Ryan, *Pain assessment: global use of the Brief Pain Inventory.* Ann Acad Med Singapore, 1994. 23(2): p. 129-38

15. Portenoy, R.K., D. Payne, and P. Jacobsen, *Breakthrough pain: characteristics and impact in patients with cancer pain.* Pain, 1999. 81(1-2):p. 129-34.

16. Melzack, R., *The McGill Pain Questionnaire: major properties and scoring methods.* Pain, 1975. 1(3): p. 277-99.

17. Melzack, R., *The short-form McGill Pain Questionnaire.* Pain, 1987. 30(2): p. 191-7

18. Dworkin, R.H., et al., *Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2).* Pain, 2009. 144(1-2): p. 35-42.

19. Bennett, M., *The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs.* Pain, 2001. 92(1-2): p. 147-57.

20. Kaki, A.M., A.Z. El-Yaski, and E. Youseif, *Identifying neuropathic pain among patients with chronic low-back pain: use of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale.* Reg Anesth Pain Med, 2005. 30(5): p. 422-8.

21. Yucel, A., et al., *Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study.* J Pain, 2004. 5(8): p. 42732.

22. Aaronson, N.K., et al., *The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.* J Natl Cancer Inst, 1993. 85(5): p.365-76

23. Barret A DJ, Morris S, Roques T. Practical Radiotherapy Planning. Breast. 4 ed. UK:Hodder Arnold; 2009:280.

24. INTERNATIONAL ATOMIC ENERGY AGENCY, Criteria for Palliation of Bone Metastasis — Clinical Applications, IAEA-TECDOC-1549, IAEA, Vienna (2007).

25. KAASA, S., et al., Prospective randomized multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases, Radiotherapy. Oncology. **79** (2006) 278–284.

26. JANJAN, N.A., et al., Clinical trials and socioeconomic implication in the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J. Palliat. Med. **12** (2009427–431.

27. CHOW, E., LUTZ, S., BEYENE, J., A single fraction for all, or an argument for fractionation tailored to fit the needs of eachindividual patient with bone metastases? Int. J. Radiat. Oncol. Biol. Phys. **55** (2003) 565–567.

28. CHOW, E., HARRIS, K., FAN, G., TSAO, M., SZE, W.M., Palliative radiotherapy trials for bone metastases: a systematicreview. J. Clin. Oncol. **25** (2007) 1423–1436.

29. MACKLIS, R.M., CORNELLI, H,. LASHER, J., Brief courses of palliative radiotherapy for metastatic bone pain, Am. J. Clin.Oncol. **21** (1998) 617–622.

30. VAN DEN HOUT, et al., Single versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utilityanalysis based on a randomized trial, J. Natl. Cancer Inst. **95** (2003) 222–229.

31. HAYMAN, J.A., LASH, K.A., TAO, M.L., HALMAN, M.A., A comparison of two methods for estimating the technical costsof external beam radiation therapy, Int. J. Radiat. Oncol. Biol. Phys. **47** (2000) 461–467.

32. WU, J.S., et al, Radiotherapy Fractionation for the Palliation of Uncomplicated Painful Bone Metastases. Practice Guidelines Report #13-2, Program in Evidence-based Care, Cancer Care Ontario Program, Toronto (2003).

33. SCOPE STEERING COMMITTEE AND SUBCOMMITTEES, Report of the American Society for Therapeutic Radiology and Oncology Working Group on the Scope of Radiation Oncology (SCOPE), Int. J. Radiat. Oncol. Biol. Phys. **54** (2002) 317–326.

34. Abdel-Wahab M, Bourque J-M, Pynda Y, et al. Status of radiotherapy resources in Africa: an International Atomic Energy Agency analysis. The Lancet Oncology 2013;14:e168- e75.

35. Murray EM. Medical and radiation oncology for breast cancer in developing countries with particular reference to locally advanced breast cancer. World Journal of Surgery 2003;27:924-7

36. Anderson BO, Cazap E, El Saghir NS, et al. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative Consensus, 2010. The Lancet Oncology 2011;12:387-98.

37. Singletary S, Connolly J. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA-A Cancer Journal for Clinicians 2006;56:37-47.

38. Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. The Breast 2006;15:584-94

39. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nature Reviews Cancer 2009;9:631-43.

40. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor–positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. Journal of Clinical Oncology 2009;27:5529-37

41. Roslyn Drummond ,Deputy Director of Radiation Oncology Peter MacCallum Cancer Institute Melbourne 3000 Victoria Australia

42. Giessen V.D. et al. Multinational assessment of some operational costs of teletherapy. Radiotherapy & Oncology, 71, 347-355, 2004

43. .Durosinmi-Etti FA. An overview of cancer management by radiotherapy in Anglophone West Africa. Int. J. Radiat Oncol. Biol. Phys. 19(5), 1263-1266; Nov 1990.

44. Yarnold J, Ashton A, Bliss J, *et al*. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiotherapy and Oncology 2005;75:9-17

45. Trialists' Group TS. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypo fractionation for treatment of early breast cancer: a randomised trial. The Lancet Oncology 2008;9:331-41.

46. Whelan TJ, Pignol J-P, Levine MN, et al. Long-term results of hypo fractionated radiation therapy for breast cancer. New England Journal of Medicine 2010;362:513-20.

47. Havilland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypo fractionation for treatment of early breast cancer: 10-year follow-up results of two randomized controlled trials. The Lancet Oncology 2013;14:1086-94.

48. Yin W .Cheb B ,Yu Y and Koag FM ,the growth of radiation oncology in mainland china during the last 10 year ,Int J Radiat Oncolo Biol Phys2008,70(3) ,795-798

49. Rostom AY, Pradhan DG, White WF. Once weekly irradiation in breast cancerInternational Journal of Radiation Oncology,Biology & Physics 1987;13:551-5.

50. Courdi A, Ortholan C, Hannoun-Lévi J-M, et al. Long-term results of hypofractionatedradiotherapy and hormonal therapy without surgery for breast cancer in elderly patients.Radiotherapy and Oncology 2006;79:156-61.

51. Ortholan C, Hannoun-Lévi J-M, Ferrero J-M, et al. Long-term results of adjuvanthypofractionated radiotherapy for breast cancer in elderly patients. International Journal ofRadiation Oncology, Biology & Physics 2005;61:154-62.

52. Kirova YM, Campana F, Savignoni A, et al. Breast-conserving treatment in the elderly:long-term results of adjuvant hypofractionated and normofractionated radiotherapy. InternationalJournal of Radiation Oncology, Biology & Physics 2009;75:76-81.